Skip to main content
. 2020 May 7;26(17):2064–2081. doi: 10.3748/wjg.v26.i17.2064

Figure 4.

Figure 4

Pathological changes in different groups. A: Dimethylhydrazine (DMH) + low-dose epigallocatechin gallate (EGCG) group showed moderate to severe dysplasia and local carcinogenesis (Hematoxylin-eosin staining, × 100); B: DMH + low-dose EGCG group showed moderate to severe dysplasia and local carcinogenesis (Hematoxylin-eosin staining, × 400); C: DMH + medium-dose EGCG group showed moderate to severe dysplasia (Hematoxylin-eosin staining, × 100); D: DMH + medium-dose EGCG group showed moderate to severe dysplasia (Hematoxylin-eosin staining, ×400); E: DMH + high-dose EGCG group showed chronic inflammation (Hematoxylin-eosin staining, × 100); F: DMH + high-dose EGCG group showed chronic inflammation (Hematoxylin-eosin staining, × 400); G: DMH group showed signet-ring cell carcinoma (Hematoxylin-eosin staining, × 100); H: DMH group showed signet-ring cell carcinoma (Hematoxylin-eosin staining, × 400).